Contact | Print version | PDF version | Send article | RSS feed

Drug development program started based on CAP Human Cell Line

New platform may provide solutions for many RA-patients around the world

05 Mar 2009 - Alloksys Life Sciences BV, CEVEC Pharmaceuticals GmbH and PharmaCell BV announced the start of Theraptech, a 2.4 million Euro therapeutic protein development program subsidized under the European Trans Bio Program.
 
The major objective of the Theraptech project is to develop a recombinant human alkaline phosphatase (rhuAP) using the novel versatile human CAP® cell line, which has been shown to efficiently express glycosylated proteins. The rhuAP produced in CAP® cells is expected to feature improved pharmacokinetic and safety profile allowing for repeated dosing of alkaline phosphatase in chronic diseases.
 
Based on a the anti-inflammatory mechanism of action of alkaline phosphatase towards e.g. TNFa, IL-6 and IL-8, as shown in both pre-clinical and clinical studies in acute conditions, Theraptech proposes it to be developed as a therapeutic protein in major chronic diseases such as Rheumatoid Arthritis. The combined expertise of the members participating in the consortium covers the entire spectrum of activities needed to drive the project from molecular biology to GMP-production and recombinant product testing in preclinical and clinical trials, pushing towards a clinical phase II compliant product within the 3-year-time frame of the project.